PTC Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for PTC Therapeutics (PTCT).

Price Target Range — 12 Quarters

Analyst Consensus — 16 Analysts

13Buy

2Hold

1Sell

Consensus RatingBuy# Analysts16Avg. Consensus PT$85Upside to Avg. PT+38.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	UBS	John Lee	Assumes	Buy	$80→$90
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$85→$75
Sep 22, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$130→$137
Sep 14, 2026	Leerink Partners	—	Assumes	Outperform	$98
Aug 14, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$120→$122
Aug 13, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$106→$109
Jul 31, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$93→$104
Jul 31, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$93→$106
Jul 20, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$95→$93
Jul 16, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$124→$130
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$82→$85
Jun 9, 2026	Citigroup	Geoff Meacham	Assumes	Neutral→Buy	$75→$108
May 27, 2026	Jefferies	Faisal Khurshid	Upgrade	Hold→Buy	$76→$85
May 8, 2026	TD Cowen	Joseph Thome	Upgrade	Hold→Buy	$75→$90
May 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$81→$82
May 8, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Overweight	$86→$95
Mar 30, 2026	Jefferies	Faisal Khurshid	Downgrade	Buy→Hold	$91→$76
Feb 23, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Overweight	$90→$92
Feb 20, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$93→$86
Feb 20, 2026	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$87→$82

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $85 to $75.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $130 to $137.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

Barclays analyst Eliana Merle maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $120 to $122.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $106 to $109.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104

Morgan Stanley analyst Jeffrey Hung maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $104.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $93 to $106.

Benzinga Newsdesk

PTC Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

PTC Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75

PRO
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137

PRO
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

PRO
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109

PRO
Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104

PRO
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106

People Also Watch

People Also Watch

PTC Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

PTC Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75

PROCantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137

PROBarclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

PROWells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109

PROMorgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104

PROWells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75

PRO
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137

PRO
Barclays Maintains Overweight on PTC Therapeutics, Raises Price Target to $122

PRO
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $109

PRO
Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104

PRO
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106